About Us
Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. We believe hepatitis C represents a large and significant unmet medical need. Our objective is to contribute to an improved treatment outcome for patients with this serious disease. We believe that meaningful improvements in treatment outcomes offer the highest likelihood for commercial acceptance of our products if approved for sale.
Anadys is developing ANA598, a non-nucleoside polymerase inhibitor of the NS5B polymerase for the treatment of hepatitis C. We have also investigated ANA773, an inducer of endogenous interferons that acts via the Toll-Like Receptor 7, or TLR7, pathway in a Phase I clinical trial in hepatitis C.
Our expertise is based on two distinct scientific approaches to treating disease. With ANA598 we are focused on developing a direct-acting antiviral, meaning a product candidate that acts by directly interacting with, and blocking the function of, a component of the virus. We discovered ANA598 through an extensive structure-based drug design program that focused on parameters we believe are critical for success in chronic viral diseases, including potency and sustained drug levels in blood. With ANA773, we are stimulating the patient's own immune system to block cells infected with the hepatitis C virus from further producing more virus particles and amplifying the infection. ANA773 stimulates the immune system through activating a key receptor on immune cells known as TLR7. Our knowledge of TLR7 is supported by an extensive preclinical program exploring the pharmacology of this receptor and through previous clinical experience with other molecules that act via the TLR7 mechanism.
Activation of the TLR7 receptor may also allow the patient’s immune system to attack cancer cells. Accordingly, we have also investigated ANA773 in a separate Phase I trial for the treatment of patients with advanced cancer.
Pending the outcome and analysis of the data from the current cohorts in the ongoing ANA773 HCV and oncology studies, we intend to manage these programs as potential out-licensing opportunities.
Anadys retains all commercialization rights to both ANA598 and ANA773, which were discovered at Anadys.
Last Updated 6/12/2009
This description contains certain forward-looking statements within the meaning of the Federal securities laws. Our results could vary, perhaps materially, from our projections or expectations. Please see our SEC filings, including our most recent 10-Q, for a discussion of the risk factors that could affect our business.
Overview